| ID Source | ID |
|---|---|
| PubMed CID | 66366 |
| CHEMBL ID | 1358662 |
| SCHEMBL ID | 610656 |
| MeSH ID | M0017775 |
| Synonym |
|---|
| dexpropranolol hcl |
| D03729 |
| dexpropranolol hydrochloride (usan) |
| ay-20694 |
| (r)-(+)-propranolol hydrochloride |
| MLS001333595 , |
| smr000875288 |
| (r)-(+)-propranolol hydrochloride, >=98% (tlc) |
| NCGC00094314-03 |
| NCGC00094314-02 |
| NCGC00094314-01 |
| ay 20694 |
| (2r)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol hydrochloride |
| A806133 |
| (2r)-1-(1-naphthalenyloxy)-3-(propan-2-ylamino)-2-propanol hydrochloride |
| ab9db0nx46 , |
| ay 20,694 |
| i.c.i. 47,319 |
| unii-ab9db0nx46 |
| dexpropranolol hydrochloride [usan] |
| ici 47319 |
| nsc 757295 |
| 2-propanol, 1-((1-methylethyl)-amino)-3-(1-naphthalenyloxy)-, hydrochoride, (r)- |
| (+)-anapriline |
| (r)-(2-hydroxy-3-(naphthyloxy)propyl)isopropylammonium chloride |
| ay-20,694 |
| einecs 235-961-7 |
| nsc-757295 |
| (r)-1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride |
| (2r)-1-((1-methylethyl)amino)-3-(naphthalen-1-yloxy)propan-2-ol hydrochloride |
| ici-47319 |
| propranolol hydrochloride, (r)- |
| CHEMBL1358662 |
| SCHEMBL610656 |
| AKOS022180739 |
| (2r)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;hydrochloride |
| (r)-(+)-1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol hydrochloride |
| 2r-(+)-propanolol hydrochloride |
| J-005855 |
| SR-01000597855-1 |
| sr-01000597855 |
| (2r)-1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol hydrochloride |
| AS-73737 |
| HY-A0295 |
| CS-0021023 |
| (r)-(+)-propranolol hcl |
| r(+)-propranolol hcl |
| BCP24272 |
| DTXSID30873365 |
| 2-propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-,hydrochloride, (2r)- |
| Q27122453 |
| (r)-propranolol (hydrochloride) |
| 2-propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-,hcl, (2r)- |
| 2-propanol,1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-,hydrochloride(1:1),(2r)- |
| 2-propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-, (2r)-, hydrochloride (1:1) |
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 5.0119 | 0.0032 | 45.4673 | 12,589.2998 | AID1705 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.1585 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 63.0957 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.5406 | 17.6392 | 96.1227 | AID2364 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 84.9214 | 23.9341 | 23.9341 | 23.9341 | AID1967 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 11.2202 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| geminin | Homo sapiens (human) | Potency | 1.6391 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 44.6684 | 0.1778 | 24.7352 | 79.4328 | AID488949 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 17.7828 | 0.0912 | 0.0912 | 0.0912 | AID488979 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 6.8660 | 0.8913 | 12.0676 | 28.1838 | AID1459; AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| large T antigen | Betapolyomavirus macacae | IC50 (µMol) | 100.0000 | 0.1600 | 24.9724 | 100.0000 | AID1903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||